I-Mab Announces Publication Of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig In JITC
Portfolio Pulse from Happy Mohamed
I-Mab (NASDAQ:IMAB), a clinical-stage biopharmaceutical company, announced the publication of a manuscript detailing the antitumor activity of its bispecific antibody givastomig in The Journal for Immuno-Therapy of Cancer. Givastomig is designed to bind to CLDN18.2-expressing cancer cells and activate T cells within these tumors, offering potential for effective immuno-therapy in gastric cancer. The drug is currently undergoing Phase 1 clinical studies in the U.S. and China, with promising results so far. The company plans to report additional clinical data later this year.
July 05, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
I-Mab's bispecific antibody givastomig shows promising antitumor activity in gastric cancer. The drug is currently in Phase 1 clinical studies with encouraging results.
The news of the promising results from the Phase 1 clinical studies of givastomig is likely to have a positive impact on I-Mab's stock. The drug's potential as an effective immuno-therapy for gastric cancer, a disease with limited treatment options, could increase investor confidence in the company's pipeline and future prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100